Table 6.

Changes in serum and urinary cystatin C concentrations in patients prescribed cisplatin-containing regimens.

# Patients analyzed	Mean cisplatin dose	Cisplatin naïve (yes/no)	# Patients with clinical AKI	Highest mean/median fold change from baseline during the observation period	Timing of peak change	References
60	50 mg/m2	Yes	13% ↓ eGFR Day 5	S: ↑ 1.1-fold	Day 5	59
35	50 mg/m2	Unknown	No SCr change	S: ↑ 1.1-fold	Day 5	62
34	60 mg/m2(3 cycles)	Yes	NE	S: ↑ 1.1-foldAfter first cycle	Days 14–28	61
57	63.4 mg/m2	Mixed	N = 1	U: ↑ 1.9-fold	Day 3	31
33	75 mg/m2	Yes	10/33 by Day 425% ↓ eGFR	U: No change at 8hNo difference in AKI and no-AKI groups		21
27	80 mg/m2	Yes	N = 2	S: ↑ 41%n = 9 ↑ 50%	Day 3	50
123	120 mg/day	Yes	NE	S: Up to ↑ 1.1-fold	Day 21	67

AKI: acute kidney injury; eGFR: estimated glomerular filtration rate; NE: not evaluated; S: serum; U: urine.

Each publication provides different definitions for the diagnosis of clinical acute kidney injury.